243 related articles for article (PubMed ID: 30280358)
1. Intranasal Surface-Modified Mosapride Citrate-Loaded Nanostructured Lipid Carriers (MOS-SMNLCs) for Treatment of Reflux Diseases: In vitro Optimization, Pharmacodynamics, and Pharmacokinetic Studies.
Hammad RW; Sanad RAB; Abdelmalk NS; Aziz RL; Torad FA
AAPS PharmSciTech; 2018 Nov; 19(8):3791-3808. PubMed ID: 30280358
[TBL] [Abstract][Full Text] [Related]
2. Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies.
Gadhave DG; Tagalpallewar AA; Kokare CR
AAPS PharmSciTech; 2019 Jan; 20(1):22. PubMed ID: 30604305
[TBL] [Abstract][Full Text] [Related]
3. Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin.
Fahmy UA; Ahmed OAA; Badr-Eldin SM; Aldawsari HM; Okbazghi SZ; Awan ZA; Bakhrebah MA; Alomary MN; Abdulaal WH; Medina C; Alhakamy NA
Int J Nanomedicine; 2020; 15():5253-5264. PubMed ID: 32801690
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
5. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
6. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.
Gabal YM; Kamel AO; Sammour OA; Elshafeey AH
Int J Pharm; 2014 Oct; 473(1-2):442-57. PubMed ID: 25062866
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
8. Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers.
El-Helw AR; Fahmy UA
Int J Nanomedicine; 2015; 10():5797-804. PubMed ID: 26396513
[TBL] [Abstract][Full Text] [Related]
9. New intranasal cross-linked mosapride xyloglucan pluronics micelles (MOS-XPMs) for reflux esophagitis disease:
Hammad RW; Sanad RA; Abdelmalak NS; Torad FA; Latif R
J Adv Res; 2020 May; 23():83-94. PubMed ID: 32089877
[TBL] [Abstract][Full Text] [Related]
10. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles.
Elnaggar YS; El-Massik MA; Abdallah OY
Int J Nanomedicine; 2011; 6():3195-205. PubMed ID: 22238508
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability.
Liu R; Liu Z; Zhang C; Zhang B
J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401
[TBL] [Abstract][Full Text] [Related]
12. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies.
Gadhave DG; Kokare CR
Drug Dev Ind Pharm; 2019 May; 45(5):839-851. PubMed ID: 30702966
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study.
El Assasy AEI; Younes NF; Makhlouf AIA
AAPS PharmSciTech; 2019 Jan; 20(2):82. PubMed ID: 30652198
[TBL] [Abstract][Full Text] [Related]
14. Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model.
Li J; Yang M; Xu W
Drug Des Devel Ther; 2018; 12():2241-2248. PubMed ID: 30050285
[TBL] [Abstract][Full Text] [Related]
15. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach.
Pardeshi CV; Rajput PV; Belgamwar VS; Tekade AR; Surana SJ
Drug Deliv; 2013; 20(1):47-56. PubMed ID: 23311653
[TBL] [Abstract][Full Text] [Related]
16. Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect.
Yin J; Hou Y; Yin Y; Song X
Int J Nanomedicine; 2017; 12():8671-8680. PubMed ID: 29263662
[TBL] [Abstract][Full Text] [Related]
17. Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer.
Devkar TB; Tekade AR; Khandelwal KR
Colloids Surf B Biointerfaces; 2014 Oct; 122():143-150. PubMed ID: 25033434
[TBL] [Abstract][Full Text] [Related]
18. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
19. Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides.
Yang G; Wu F; Chen M; Jin J; Wang R; Yuan Y
Int J Nanomedicine; 2019; 14():2267-2280. PubMed ID: 31015758
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-loaded Nanolipidic Carriers with Improved Oral Bioavailability and Anticancer Activity against Human Liver Carcinoma.
Harshita ; Barkat MA; Rizwanullah M; Beg S; Pottoo FH; Siddiqui S; Ahmad FJ
AAPS PharmSciTech; 2019 Jan; 20(2):87. PubMed ID: 30675689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
